PIK3CA mutations and copy number gains in human lung cancers

Hiromasa Yamamoto, Hisayuki Shigematsu, Masaharu Nomura, William W. Lockwood, Mitsuo Sato, Naoki Okumura, Junichi Soh, Makoto Suzuki, Ignacio I. Wistuba, Kwun M. Fong, Huei Lee, Shinichi Toyooka, Hiroshi Date, Wan L. Lam, John D. Minna, Adi F. Gazdar

Research output: Contribution to journalArticle

302 Citations (Scopus)

Abstract

We investigated the frequency and function of mutations and increased copy number of the PIK3CA gene in lung cancers. PIK3CA mutations are one of the most common gene changes present in human cancers. We analyzed the mutational status of exons 9 and 20 and gene copy number of PIK3CA using 86 non-small cell lung cancer (NSCLC) cell lines, 43 small cell lung cancer (SCLC) cell lines, 3 extrapulmonary small cell cancer (ExPuSC) cell lines, and 691 resected NSCLC tumors and studied the relationship between PIK3CA alterations and mutational status of epidermal growth factor receptor (EGFR) signaling pathway genes (EGFR, KRAS, HER2, and BRAF). We also determined PIK3CA expression and activity and correlated the findings with effects on cell growth. We identified mutations in 4.7% of NSCLC cell lines and 1.6% of tumors of all major histologic types. Mutations in cell lines of small cell origin were limited to two ExPuSC cell lines. PIK3CA copy number gains were more frequent in squamous cell carcinoma (33.1%) than in adenocarcinoma (6.2%) or SCLC lines (4.7%). Mutational status of PIK3CA was not mutually exclusive to EGFR or KRAS. PIK3CA alterations were associated with increased phosphatidylinositol 3-kinase activity and phosphorylated Akt expression. RNA interference-mediated knockdown of PIK3CA inhibited colony formation of cell lines with PIK3CA mutations or gains but was not effective in PIK3CA wild-type cells. PIK3CA mutations or gains are present in a subset of lung cancers and are of functional importance.

Original languageEnglish
Pages (from-to)6913-6921
Number of pages9
JournalCancer Research
Volume68
Issue number17
DOIs
Publication statusPublished - Sep 1 2008
Externally publishedYes

Fingerprint

Lung Neoplasms
Cell Line
Mutation
Non-Small Cell Lung Carcinoma
Gene Dosage
Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Neoplasms
Phosphatidylinositol 3-Kinase
erbB-1 Genes
Mutation Rate
RNA Interference
Tumor Cell Line
Squamous Cell Carcinoma
Exons
Adenocarcinoma
Growth
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura, N., ... Gazdar, A. F. (2008). PIK3CA mutations and copy number gains in human lung cancers. Cancer Research, 68(17), 6913-6921. https://doi.org/10.1158/0008-5472.CAN-07-5084

PIK3CA mutations and copy number gains in human lung cancers. / Yamamoto, Hiromasa; Shigematsu, Hisayuki; Nomura, Masaharu; Lockwood, William W.; Sato, Mitsuo; Okumura, Naoki; Soh, Junichi; Suzuki, Makoto; Wistuba, Ignacio I.; Fong, Kwun M.; Lee, Huei; Toyooka, Shinichi; Date, Hiroshi; Lam, Wan L.; Minna, John D.; Gazdar, Adi F.

In: Cancer Research, Vol. 68, No. 17, 01.09.2008, p. 6913-6921.

Research output: Contribution to journalArticle

Yamamoto, H, Shigematsu, H, Nomura, M, Lockwood, WW, Sato, M, Okumura, N, Soh, J, Suzuki, M, Wistuba, II, Fong, KM, Lee, H, Toyooka, S, Date, H, Lam, WL, Minna, JD & Gazdar, AF 2008, 'PIK3CA mutations and copy number gains in human lung cancers', Cancer Research, vol. 68, no. 17, pp. 6913-6921. https://doi.org/10.1158/0008-5472.CAN-07-5084
Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Research. 2008 Sep 1;68(17):6913-6921. https://doi.org/10.1158/0008-5472.CAN-07-5084
Yamamoto, Hiromasa ; Shigematsu, Hisayuki ; Nomura, Masaharu ; Lockwood, William W. ; Sato, Mitsuo ; Okumura, Naoki ; Soh, Junichi ; Suzuki, Makoto ; Wistuba, Ignacio I. ; Fong, Kwun M. ; Lee, Huei ; Toyooka, Shinichi ; Date, Hiroshi ; Lam, Wan L. ; Minna, John D. ; Gazdar, Adi F. / PIK3CA mutations and copy number gains in human lung cancers. In: Cancer Research. 2008 ; Vol. 68, No. 17. pp. 6913-6921.
@article{d7e5cb65c25247a599119c156ef7fc55,
title = "PIK3CA mutations and copy number gains in human lung cancers",
abstract = "We investigated the frequency and function of mutations and increased copy number of the PIK3CA gene in lung cancers. PIK3CA mutations are one of the most common gene changes present in human cancers. We analyzed the mutational status of exons 9 and 20 and gene copy number of PIK3CA using 86 non-small cell lung cancer (NSCLC) cell lines, 43 small cell lung cancer (SCLC) cell lines, 3 extrapulmonary small cell cancer (ExPuSC) cell lines, and 691 resected NSCLC tumors and studied the relationship between PIK3CA alterations and mutational status of epidermal growth factor receptor (EGFR) signaling pathway genes (EGFR, KRAS, HER2, and BRAF). We also determined PIK3CA expression and activity and correlated the findings with effects on cell growth. We identified mutations in 4.7{\%} of NSCLC cell lines and 1.6{\%} of tumors of all major histologic types. Mutations in cell lines of small cell origin were limited to two ExPuSC cell lines. PIK3CA copy number gains were more frequent in squamous cell carcinoma (33.1{\%}) than in adenocarcinoma (6.2{\%}) or SCLC lines (4.7{\%}). Mutational status of PIK3CA was not mutually exclusive to EGFR or KRAS. PIK3CA alterations were associated with increased phosphatidylinositol 3-kinase activity and phosphorylated Akt expression. RNA interference-mediated knockdown of PIK3CA inhibited colony formation of cell lines with PIK3CA mutations or gains but was not effective in PIK3CA wild-type cells. PIK3CA mutations or gains are present in a subset of lung cancers and are of functional importance.",
author = "Hiromasa Yamamoto and Hisayuki Shigematsu and Masaharu Nomura and Lockwood, {William W.} and Mitsuo Sato and Naoki Okumura and Junichi Soh and Makoto Suzuki and Wistuba, {Ignacio I.} and Fong, {Kwun M.} and Huei Lee and Shinichi Toyooka and Hiroshi Date and Lam, {Wan L.} and Minna, {John D.} and Gazdar, {Adi F.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-07-5084",
language = "English",
volume = "68",
pages = "6913--6921",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - PIK3CA mutations and copy number gains in human lung cancers

AU - Yamamoto, Hiromasa

AU - Shigematsu, Hisayuki

AU - Nomura, Masaharu

AU - Lockwood, William W.

AU - Sato, Mitsuo

AU - Okumura, Naoki

AU - Soh, Junichi

AU - Suzuki, Makoto

AU - Wistuba, Ignacio I.

AU - Fong, Kwun M.

AU - Lee, Huei

AU - Toyooka, Shinichi

AU - Date, Hiroshi

AU - Lam, Wan L.

AU - Minna, John D.

AU - Gazdar, Adi F.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - We investigated the frequency and function of mutations and increased copy number of the PIK3CA gene in lung cancers. PIK3CA mutations are one of the most common gene changes present in human cancers. We analyzed the mutational status of exons 9 and 20 and gene copy number of PIK3CA using 86 non-small cell lung cancer (NSCLC) cell lines, 43 small cell lung cancer (SCLC) cell lines, 3 extrapulmonary small cell cancer (ExPuSC) cell lines, and 691 resected NSCLC tumors and studied the relationship between PIK3CA alterations and mutational status of epidermal growth factor receptor (EGFR) signaling pathway genes (EGFR, KRAS, HER2, and BRAF). We also determined PIK3CA expression and activity and correlated the findings with effects on cell growth. We identified mutations in 4.7% of NSCLC cell lines and 1.6% of tumors of all major histologic types. Mutations in cell lines of small cell origin were limited to two ExPuSC cell lines. PIK3CA copy number gains were more frequent in squamous cell carcinoma (33.1%) than in adenocarcinoma (6.2%) or SCLC lines (4.7%). Mutational status of PIK3CA was not mutually exclusive to EGFR or KRAS. PIK3CA alterations were associated with increased phosphatidylinositol 3-kinase activity and phosphorylated Akt expression. RNA interference-mediated knockdown of PIK3CA inhibited colony formation of cell lines with PIK3CA mutations or gains but was not effective in PIK3CA wild-type cells. PIK3CA mutations or gains are present in a subset of lung cancers and are of functional importance.

AB - We investigated the frequency and function of mutations and increased copy number of the PIK3CA gene in lung cancers. PIK3CA mutations are one of the most common gene changes present in human cancers. We analyzed the mutational status of exons 9 and 20 and gene copy number of PIK3CA using 86 non-small cell lung cancer (NSCLC) cell lines, 43 small cell lung cancer (SCLC) cell lines, 3 extrapulmonary small cell cancer (ExPuSC) cell lines, and 691 resected NSCLC tumors and studied the relationship between PIK3CA alterations and mutational status of epidermal growth factor receptor (EGFR) signaling pathway genes (EGFR, KRAS, HER2, and BRAF). We also determined PIK3CA expression and activity and correlated the findings with effects on cell growth. We identified mutations in 4.7% of NSCLC cell lines and 1.6% of tumors of all major histologic types. Mutations in cell lines of small cell origin were limited to two ExPuSC cell lines. PIK3CA copy number gains were more frequent in squamous cell carcinoma (33.1%) than in adenocarcinoma (6.2%) or SCLC lines (4.7%). Mutational status of PIK3CA was not mutually exclusive to EGFR or KRAS. PIK3CA alterations were associated with increased phosphatidylinositol 3-kinase activity and phosphorylated Akt expression. RNA interference-mediated knockdown of PIK3CA inhibited colony formation of cell lines with PIK3CA mutations or gains but was not effective in PIK3CA wild-type cells. PIK3CA mutations or gains are present in a subset of lung cancers and are of functional importance.

UR - http://www.scopus.com/inward/record.url?scp=52049099853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049099853&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-5084

DO - 10.1158/0008-5472.CAN-07-5084

M3 - Article

VL - 68

SP - 6913

EP - 6921

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 17

ER -